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Aortic stenosis is the most common type of valve disease in the adults. Until recently its
treatment was an exclusive domain of cardiac surgery. At the same time the aortic valve
replacement (SAVR) was not indicated in about 1/3 of the patients, though the prognosis of
conservatively treated patients is very unfavourable with one-year mortality rate of 50%.
These facts were the main reasons for starting a new interventional era of the aortic valve
disease therapy in 2002 and from 2007 two types of valves fixed in stents have been
commercially available.
In the early phase the transcatheter aortic valve implantation (TAVI) was used just in
patients with contraindication to SAVR or with high perioperative risk after surgery. Before
applying this therapy to less risky patients some problems have to be solved: 1. clinical
impact of the relatively high rate of paravalvular leaks and 2. long-term function of the
implanted valve in follow-up exceeding 5 years.
In the Czech Republic the first TAVI was performed in Prague, IKEM in December 2008.
During a short period of time the TAVI programme was initiated also in other complex
cardiovascular centres in Hradec Kralove, Brno, Prague—FN Kralovske Vinohrady and
Trinec. Including the later starting centres (Usti n. Labem, Olomouc, Ceske Budejovice and
other three centres in Prague—Nemocnice na Homolce, FN Motol and VFN) there is a total
of 11 centres providing the TAVI at present. All centres except one (FN Motol) are part of the
Czech TAVI Registry that was developed with the support of the Czech Society of
Cardiology and started on 1 September, 2010. In general and more theoretically there are
two parts of the Registry: 1. ‘‘Retrospective’’ including all the TAVI procedures from the
beginning of the TAVI programme in the Czech Republic that was terminated on June 30,
2011 and 2. ‘‘Prospective’’ that has been following. Institute of Biostatistics and Analyses of
Masaryk University takes care of the online and anonymized database.
The results of the national Czech TAVI Registry should help to answer the clinical
relevant questions mentioned above.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Aortic stenosis is the most common type of valve disease in the
adults. Until recently its treatment was an exclusive domain of
cardiac surgery. At the same time the aortic valve replacement
(SAVR) was not indicated in about 1/3 of the patients [1] though
the prognosis of conservatively treated patients is very unfa-
vourable with one-year mortality rate of 50%. These facts
were the main reasons for starting a new interventional era
of the aortic valve disease therapy in 2002 [2]. From 2007
two new types of valves in stents have been commercially
available—balloon expandable Edwards Sapian valve (Edwards
Lifesciences, Inc., Irvine, California) and the selfexpanding
CoreValve (Medtronic, Inc., Minnesota, USA) [3,4]. If the stan-
dard femoral approach is impossible to use there are severalFig. 1 – Patient identifier, demographics and heart-team
decision.
Fig. 2 – Calculationalternatives like the transapical, transsubclavian, transaortic or
recently described transcarotid approaches. On the contrary to
SAVR the native severely diseased aortic valve remains in place
enabling the new valve to reach a stable position.
In the early phase the transcatheter aortic valve implanta-
tion (TAVI) was used just in patients with contraindication to
SAVR or with high perioperative risk after surgery. In some
countries the increased experience and good short- and
middle-term results of TAVI resulted in broad application of
TAVI nearly as equivalent to SAVR. Some problems have to be
solved before general acception of such strategy: 1. What
clinical impact will have the relative high rate of paravalvular
leaks? and 2. What will be the function of the implanted
valve in real long-term follow-up exceeding 5 years?
Besides the randomized trials comparing the TAVI vs. SAVR
[5,6] and several registries [7–9] it is important to get also our
own national data. The Czech TAVI Registry comprises the
use of both currently available types of valves and the results
can help to answer the above mentioned and clinically
relevant questions.2. TAVI programme in the Czech Republic
In the Czech Republic the first TAVI was performed in
Prague, IKEM in December 2008 [10]. During a short period
of time the TAVI programme was initiated also in other
complex cardiovascular centres in Hradec Kralove [11], Brno
[12], Prague—FN Kralovske Vinohrady and Trinec. Including
the later starting centres (Usti n. Labem, Olomouc, Ceskeof EuroSCORE.
Fig. 3 – Medical history, CAD risk factors and the type of previous interventions. (CAD – coronary artery disease).
Fig. 4 – Pre-procedural clinical status.
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Homolce, FN Motol and VFN) there is a total of 11 centres
providing the TAVI at present. All centres except one (FN
Motol) are part of the Czech TAVI Registry that was developed
with the support of the Czech Society of Cardiology and
started on September 1, 2010. The structure of the Registry
was planned with the valuable help of Professor Carlo di
Mario, the President of the European Association of PCI
(EAPCI) at that time. In general and more theoretically there
are two parts of the Registry: 1. ‘‘Retrospective’’ including all
the TAVI procedures from the beginning of the TAVI
programme in the Czech Republic that was terminated on
June 30, 2011 and 2. ‘‘Prospective’’ that has been following.
Institute of Biostatistics and Analyses of Masaryk University
takes care of the online and anonymized database. Since
April 2012 the centres receive regularly benchmarks showing
their own results in comparison with the mean data from the
whole country. Dataset described in the paper enables a very
good collaboration with the ongoing European TCVT (Trans-
Cutaneous Valve Therapy) Pilot Registry supported by the
European Society of Cardiology. Just the Czech Republic and
Poland represent the middle-east European countries in this
important project that started in the beginning of 2012.3. Czech TAVI Registry—dataset
The web-based Czech TAVI Registry has two main parts
describing the hospital phase and follow-up of the patients
at 1 month and yearly after the procedure.1. Hospital phase
a. Pre-procedural data (Figs. 1–6)
b. Procedural data (Figs. 7 and 8)
c. Post-procedural data (Figs. 6, 9, 10 and 11)Fig. 6 – In-hospital biology before and after TAVI.
2. Follow-up (Fig. 12)Fig. 5 – Echocardiographic anduring each follow-up are collected. Separate questionnaire hasThe total of 222 in-hospital parametres and 19 parametres
to be filled in if the patient dies. All the data are marked as
Pending – Completed – Uncollectable.
General description of the Czech TAVI Registry can be
found at http://www.registry.cz/index.php?pg=projekty&
prid=60. Direct link to the database (http://tavi.registry.cz) is
used by the investigators from participating centres.4. Other national and international TAVI
registries
There are several other national and international ongoing
TAVI registries both in Europe and outside Europe, e.g.,d angiographic findings.
Fig. 7 – Procedural data.
Fig. 8 – Immediate procedural outcome and complications.
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Fig. 9 – Post-procedural in-hospital complications.
Fig. 10 – Echocardiographic findings before discharge.
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Fig. 11 – Dataset at discharge.
Fig. 12 – Follow-up evaluation.
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Swiss, UK, WIN TAVI Registries, STS/ACC TVT Registry and
already mentioned European TCVT Pilot Registry. The high
number of different TAVI registries and ongoing big trials
(PARTNER 2, SURTAVI) may serve as a potent marker of the
importance of TAVI. In relatively near future the optimal
treatment strategy of patients with severe aortic stenoses
might be changed and TAVI has the potential to do it.5. Conclusion
Czech TAVI Registry is a nation-wide registry including more
than 90% of all the Czech centres and about 95% of all the
TAVI procedures performed in the Czech Republic. The first
analyses with at least 1-year outcome of 250 patients will be
completed in 2012.Acknowledgement
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